Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing Polpharma Group one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Biologics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.
Grünenthal in US$300m deal with AstraZeneca
Latest NewsGerman Grünenthal Group has entered into an agreement to acquire the global rights to AstraZenecas migraine treatment Zolmitriptan.
Biocartis launches partnership in liquid biopsy
Latest NewsBelgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.
The Difference of One Simple Sort
Sponsored PublicationsOne researcher, one sorter, one cell, many discoveries. BD is dedicated to developing easy-to-use cell sorting technologies that simplify accurate and reliable flow cytometry.
Biomanufacturing: Why single-use?
OpinionPharmalink: Launching into Phase III
AppointmentsMerck KGaA and F-star in €1bn deal
Latest NewsGerman Merck KGaA has secured an option on UKs F-Star Biotechnology Ltds preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.
Metrion Biosciences: Developing the business
AppointmentsBicycle raises £40m
Latest NewsCambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties.
EC and EMA provide Brexit guidance
Latest NewsUK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.
Addex further improves liquidity
Latest NewsFollowing a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinsons and ADX71441.